Xinyi Jiang, Sarah Connolly, Andrea E Strahan, Liz Rivera Blanco, Christina A Mikosz, Gery P Guy, Deborah Dowell
{"title":"2022 年 7 月至 2023 年 9 月接受药物使用治疗评估的年龄≥18 岁成人中报告的 Xylazine 使用情况 - 美国。","authors":"Xinyi Jiang, Sarah Connolly, Andrea E Strahan, Liz Rivera Blanco, Christina A Mikosz, Gery P Guy, Deborah Dowell","doi":"10.15585/mmwr.mm7326a2","DOIUrl":null,"url":null,"abstract":"<p><p>Xylazine has been increasingly detected in illegally manufactured fentanyl (IMF) products and overdose deaths in the United States; most xylazine-involved overdose deaths involve IMF. A convenience sample of U.S. adults aged ≥18 years was identified from those evaluated for substance use treatment during July 2022-September 2023. Data were collected using the Addiction Severity Index-Multimedia Version clinical assessment tool. Among 43,947 adults, 6,415 (14.6%) reported IMF or heroin as their primary lifetime substance-use problem; 5,344 (12.2%) reported recent (i.e., past-30-day) IMF or heroin use. Among adults reporting IMF or heroin as their primary lifetime substance-use problem, 817 (12.7%) reported ever using xylazine. Among adults reporting recent IMF or heroin use, 443 (8.3%) reported recent xylazine use. Among adults reporting IMF or heroin use recently or as their primary lifetime substance-use problem, those reporting xylazine use reported a median of two past nonfatal overdoses from any drug compared with a median of one overdose among those who did not report xylazine use; as well, higher percentages of persons who reported xylazine use reported other recent substance use and polysubstance use. Provision of nonjudgmental care and services, including naloxone, wound care, and linkage to and retention of persons in effective substance use treatment, might reduce harms including overdose among persons reporting xylazine use.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 26","pages":"594-599"},"PeriodicalIF":25.4000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221633/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reported Xylazine Use Among Adults Aged ≥18 Years Evaluated for Substance Use Treatment - United States, July 2022-September 2023.\",\"authors\":\"Xinyi Jiang, Sarah Connolly, Andrea E Strahan, Liz Rivera Blanco, Christina A Mikosz, Gery P Guy, Deborah Dowell\",\"doi\":\"10.15585/mmwr.mm7326a2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Xylazine has been increasingly detected in illegally manufactured fentanyl (IMF) products and overdose deaths in the United States; most xylazine-involved overdose deaths involve IMF. A convenience sample of U.S. adults aged ≥18 years was identified from those evaluated for substance use treatment during July 2022-September 2023. Data were collected using the Addiction Severity Index-Multimedia Version clinical assessment tool. Among 43,947 adults, 6,415 (14.6%) reported IMF or heroin as their primary lifetime substance-use problem; 5,344 (12.2%) reported recent (i.e., past-30-day) IMF or heroin use. Among adults reporting IMF or heroin as their primary lifetime substance-use problem, 817 (12.7%) reported ever using xylazine. Among adults reporting recent IMF or heroin use, 443 (8.3%) reported recent xylazine use. Among adults reporting IMF or heroin use recently or as their primary lifetime substance-use problem, those reporting xylazine use reported a median of two past nonfatal overdoses from any drug compared with a median of one overdose among those who did not report xylazine use; as well, higher percentages of persons who reported xylazine use reported other recent substance use and polysubstance use. Provision of nonjudgmental care and services, including naloxone, wound care, and linkage to and retention of persons in effective substance use treatment, might reduce harms including overdose among persons reporting xylazine use.</p>\",\"PeriodicalId\":18637,\"journal\":{\"name\":\"MMWR. Morbidity and mortality weekly report\",\"volume\":\"73 26\",\"pages\":\"594-599\"},\"PeriodicalIF\":25.4000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221633/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MMWR. Morbidity and mortality weekly report\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15585/mmwr.mm7326a2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7326a2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
摘要
在美国,越来越多的非法制造的芬太尼(IMF)产品和用药过量死亡病例中检测到了赛拉嗪;大多数涉及赛拉嗪的用药过量死亡病例都与芬太尼有关。我们从 2022 年 7 月至 2023 年 9 月期间接受药物使用治疗评估的人中抽取了年龄≥18 岁的美国成年人作为方便样本。数据使用成瘾严重程度指数多媒体版临床评估工具收集。在 43,947 名成人中,有 6,415 人(14.6%)报告 IMF 或海洛因是他们一生中主要的药物使用问题;有 5,344 人(12.2%)报告最近(即过去 30 天内)使用过 IMF 或海洛因。在报告 IMF 或海洛因是其一生中主要药物滥用问题的成年人中,有 817 人(12.7%)报告曾经使用过甲苯咪唑。在报告最近使用过 IMF 或海洛因的成年人中,有 443 人(8.3%)报告最近使用过异丙嗪。在报告最近使用过 IMF 或海洛因或将其作为终生主要药物滥用问题的成年人中,报告使用过羟丙甲嗪的人报告过去因任何药物导致的非致命性用药过量的次数中位数为两次,而未报告使用过羟丙甲嗪的人的用药过量次数中位数为一次;此外,报告使用过羟丙甲嗪的人报告最近使用过其他药物和使用过多种药物的比例也较高。提供非评判性的护理和服务,包括纳洛酮、伤口护理、联系并继续提供有效的药物使用治疗,可能会减少报告使用过二甲嗪的人的危害,包括用药过量。
Reported Xylazine Use Among Adults Aged ≥18 Years Evaluated for Substance Use Treatment - United States, July 2022-September 2023.
Xylazine has been increasingly detected in illegally manufactured fentanyl (IMF) products and overdose deaths in the United States; most xylazine-involved overdose deaths involve IMF. A convenience sample of U.S. adults aged ≥18 years was identified from those evaluated for substance use treatment during July 2022-September 2023. Data were collected using the Addiction Severity Index-Multimedia Version clinical assessment tool. Among 43,947 adults, 6,415 (14.6%) reported IMF or heroin as their primary lifetime substance-use problem; 5,344 (12.2%) reported recent (i.e., past-30-day) IMF or heroin use. Among adults reporting IMF or heroin as their primary lifetime substance-use problem, 817 (12.7%) reported ever using xylazine. Among adults reporting recent IMF or heroin use, 443 (8.3%) reported recent xylazine use. Among adults reporting IMF or heroin use recently or as their primary lifetime substance-use problem, those reporting xylazine use reported a median of two past nonfatal overdoses from any drug compared with a median of one overdose among those who did not report xylazine use; as well, higher percentages of persons who reported xylazine use reported other recent substance use and polysubstance use. Provision of nonjudgmental care and services, including naloxone, wound care, and linkage to and retention of persons in effective substance use treatment, might reduce harms including overdose among persons reporting xylazine use.
期刊介绍:
The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC).
Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.
MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.